published meta-analysis   sensitivity analysis   studies

niclosamide in COVID 19 hospitalized - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsAbdulamir, 2021 1.00 [0.20; 5.12] 1.00[0.20; 5.12]Abdulamir, 202110%150NAnot evaluable deathsdetailed resultsAbdulamir, 2021 1.00 [0.20; 5.12] 1.00[0.20; 5.12]Abdulamir, 202110%150NAnot evaluable recoverydetailed resultsAbdulamir, 2021 1.00 [0.20; 5.12] 1.00[0.20; 5.12]Abdulamir, 202110%150NAnot evaluable0.52.01.0relative treatment effectwww.metaEvidence.org2024-03-28 18:33 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 95,94,90,91 - treatments: 961 - roots T: 290